Dextrose Monohydrate 10% Injection Shortage Status
Areazine synthesizes this FDA drug-shortage notice directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
Dextrose Monohydrate 10% Injection is currently listed in the FDA database, with all manufacturers reporting availability despite the ongoing status.
What this FDA drug-shortage notice tells you, and what most readers miss
This notice was issued by FDA on April 7, 2026 and geographically references United States. Its severity classification of "low" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Drug Shortages - determines the regulatory framework behind it, which shapes what mitigations (alternative therapies, allocation timelines, manufacturer guidance) are available and which agency holds oversight.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are drug-shortage, fda, medication, Dextrose Monohydrate 10% Injection.
What's in Shortage
Generic name: Dextrose Monohydrate 10% Injection Brand name: DEXTROSE Dosage form: Injection Therapeutic category: Endocrinology/Metabolism, Gastroenterology, Other, Pediatric Current status: Current Initial posting date: 03/01/2022 Last updated: 04/02/2026
Which Manufacturers Are Affected
- Fresenius Kabi USA, LLC: Available. Related info: Check wholesalers for inventory. Presentation: Dextrose 10% In Plastic Container, Injection, 100 mg/1 mL (NDC 63323-824-76). Contact info: 888-386-1300
- Baxter Healthcare: Available. Presentation: Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-04). Contact info: 888-229-0001
- Baxter Healthcare: Available. Presentation: Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-02). Contact info: 888-229-0001
- Fresenius Kabi USA, LLC: Available. Related info: Check wholesalers for inventory. Presentation: Dextrose 10% In Plastic Container, Injection, 100 mg/1 mL (NDC 63323-824-74). Contact info: 888-386-1300
- Baxter Healthcare: Available. Presentation: Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-03). Contact info: 888-229-0001
- Fresenius Kabi USA, LLC: Available. Related info: Check wholesalers for inventory. Presentation: Dextrose 10% In Plastic Container, Injection, 100 mg/1 mL (NDC 63323-824-75). Contact info: 888-386-1300
Why There's a Shortage
No specific reason was provided in the source data.
What Patients Should Do
Patients are advised to speak with their pharmacist or healthcare provider to check the latest availability of Dextrose Monohydrate 10% Injection. They can also contact the manufacturer directly for more information. Please remember that patients should consult their healthcare provider for any medical advice and not make changes to their treatment without professional guidance.
Source
Information is attributed to the FDA Drug Shortage Database.
Original source: FDA Official Notice ↗
Related Drug Shortages
All Drug Shortages →Nationwide notices with similar length or severity timing 8
Two Areazine-derived peer sets for this FDA drug-shortage notice: nearest notices by body length and by same severity near the same agency date. Peers come from other categories so they are not the same-feed Related list above.
Similar body length
Nearest notices by article body length (1,953 characters here).
Similar severity timing
Same severity (low) notices issued closest in time to April 7, 2026.
Frequently Asked Questions
Common questions about this FDA drug-shortage notice.